Recent Trends in Hypertension Genetics Research by Padma Tirunilai & Padma Gunda
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
6 
Recent Trends in Hypertension  
Genetics Research 
Padma Tirunilai and Padma Gunda 
Dept. of Genetics, 
Osmania University, 
Hyderabad, 
India 
1. Introduction 
Human genome encompasses several thousands of genes which when fail to function 
normally lead to a defective phenotype expressed sometimes as a disease or disorder. 
These diseases or disorders may be simple or complex depending upon the nature and 
number of genes controlling the phenotypes and also their interaction with several other 
confounding demographic and environmental factors leading to a mosaic pattern of 
aetiology. Essential hypertension is one such common complex condition prevalent in 
most of the world populations and stands as a major risk factor for cardio-, cerebro and 
renovascular diseases (Kearney et al., 2005) adding to the mortality rate when the patients 
are not treated promptly and managed with proper surveillance. It also causes enormous 
financial burden to the patients and also nation’s economy. This necessitates the need to 
establish the causes with possible measures for prevention and cure of the condition 
especially in view of its high prevalence in several developed and developing countries. 
Research conducted especially in the past two decades were focused more on 
understanding the etiological factors including genetic components and their interaction 
with several other factors with a thrust to look for more appropriate therapeutic measures 
for essential hypertension (EHT). 
Regulation of blood pressure is important to maintain adequate blood flow in the body. By 
definition, blood pressure is the pressure of the blood flowing through the arteries. It 
depends on the flow of the blood pumped by the heart and the resistance exerted by the 
blood vessels against the flow. If the pressure is high, heart is forced to work harder. Based 
on the aetiology, hypertension is further grouped into two major groups viz., a) Essential or 
Primary Hypertension which is caused due to unknown etiology and has no specific origin 
but is strongly associated with life style habits representing 90-95 % of the diagnosed cases 
and b) Secondary Hypertension which arises due to preexisting medical conditions such as 
congestive heart failure, arteriosclerosis and disorders of kidney, liver, adrenal and thyroid 
glands. It accounts to 5 to 10 % of the hypertensive cases and diagnosed by various clinical 
laboratory and other tests. Apart from these two types, other types of hypertension are also 
diagnosed based on their characteristic manifestations (Table -1)     
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White coat Hypertension           
 
- 
 
BP high in doctor’s office 
Systolic Hypertension               - High SBP but normal DBP (age related) 
Malignant Hypertension            - Acute uncontrolled Blood Pressure 
Labile Hypertension                   - Variable Blood Pressure   
Accelerated Hypertension           - Severe Blood Pressure of recent origin 
Borderline Hypertension             - Blood Pressure in the grey zone 
Pseudo Hypertension                  - Due to rigidity of the artery (seen in elders) 
Pulmonary Hypertension            - High Blood Pressure in pulmonary circulation 
Renovascular Hypertension        - Due to narrowed renal artery 
Pre-eclampsia                             - Pregnancy induced 
Secondary Hypertension            - Arising from a identifiable disorder 
Table 1. Types of blood pressure disorders. 
The rhythmic contraction and relaxation of heart creates pressure which is recorded as 
Systolic blood pressure (SBP) when the heart contracts and Diastolic Blood Pressure (DBP) 
when the heart relaxes. BP levels are traditionally expressed in millimetres of mercury (1 
mmHg = 133 Pascal) in the mercury column of sphygmomanometer and is usually around 
120mmHg systolic and 80mmHg diastolic (120/80mmHg) in a normal individual. As per 
JNC VII (2003) report, based on SBP and DBP levels, individuals are grouped into four 
classes as given in Table-2. An adult with consistent systolic pressure of 140mmHg or higher 
and/ or a consistent diastolic pressure of 90mmHg or higher is considered to be 
hypertensive. 
 
 
Systolic BP 
(mm/ Hg) 
Diastolic BP 
(mm /Hg) 
Optimal <120 and <80 
Normal < 130 and < 85 
Prehypertension 130-139 or 85-89 
Hypertension   
Stage 1 (mild) 140 - 159 or  90 – 99 
Stage 2 (moderate) 160 -179 or 100 – 109 
Stage 3 (severe) ≥180 and  ≥ 110 
Isolated Systolic hypertension ≥140 and <90 
Table 2. Classification of blood pressure levels.  
2. Factors influencing hypertension 
Essential Hypertension is a common complex condition displaying substantial public health 
problem. As a multifactorial condition it involves action of several genes in conjecture with 
epidemiologic (environmental and demographic) factors manifesting finally into a defined 
phenotype Hypertension. Hypertension is found to affect 25-35% of adult and 60-70% of 
elderly population above the age of 70yrs both among the population of developed and 
developing countries (Staessen et al, 2003). Variation in the prevalence of EHT depends on 
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the ethnicity of the population like being higher in American Blacks (32.4%) as compared to 
Whites (23.3%) and Mexican Americans (22.6%) (Oscar et al., 2000). Among American Blacks 
the condition occurs with greater severity and is associated with high rate of morbidity and 
mortality due to stroke, cardiac failure, left ventricular hypertrophy and end stage renal 
disease. While much is known about demographic and environmental factors that 
predispose an individual to the development of essential hypertension, the nature of the 
genetic factors that increase susceptibility to the condition remain virtually unknown. 
Studies on the epidemiology of hypertension revealed substantial effect of age, gender, body 
mass index, smoking, high alcohol intake, insulin resistance and also diet with high intake 
of salt, and low intake of potassium and calcium (Stanton et al., 1982; Appel et al, 1997, 
Oscar et al., 2000). Some of these factors like obesity and alcohol consumption are additive 
and modifiable and thus influence variations in blood pressure and expression of  
hypertension phenotype. Other factors which are non-modifiable like age, gender, genetic 
factors etc., do not influence the variations in blood pressure and hence the associated risk 
levels (Fig - 1). In fact the factors like obesity, cholesterol levels etc., remain in an individual 
more or less stable over time while blood pressure levels keep changing several times even 
in a day due to the action of multiple physiological pathways to maintain the appropriate 
levels. Interaction between the hypertensinogenic factors and susceptibility causing genetic 
factors that have small effects poses a great challenge in unravelling the links, causes and 
management of hypertension. 
 
Fig. 1. Modifiable and Non-Modifiable factors influencing onset of essential hypertension. 
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Age is recognized as a non-modifiable risk factor for high blood pressure with continuous 
increase in SBP and decrease in DBP levels with ageing throughout ones life. Onset of 
elevated DBP is usually observed from 35-40yrs due to multiple metabolic, physiologic or 
genetic reasons while increase in SBP among the aged is observed due to arteriosclerosis or 
hardening of arteries, decrease in kidney function and physical activity. In many 
populations men show higher prevalence of hypertension with early onset than women. It 
has been suggested that estrogen levels have lowering effect on blood pressure in young 
women but a dramatic increase in the incidence of hypertension is observed in the 
postmenopausal women. Obesity and overweight also pose a major risk for chronic 
diseases including hypertension. Obesity induces a high secretion of insulin which brings in 
many modifications in the body like i) Thickening of the vessels which is responsible for an 
increase in the rigidity of arteries and in turn the blood pressure, ii) Increase in the cardiac 
output due to the secretion of increased adrenalin, iii) Induction of reabsorption of water 
and salt by the kidney which increases the blood volume and consequently the blood 
pressure iv) Over-sensitiveness to sodium which is known to increase the rigidity of the 
peripheral arteries. 
Body Mass Index (BMI) is a simple index of weight-for-height that is commonly used to 
classify underweight, overweight and obesity in adults. It is defined as the weight in 
kilograms divided by the square of the height in meters (kg/m2). 
 BMI = Mass (Kg) / Height (m)2
BMI of <18.5 – Underweight; 18.5-24.9 – Normal; 25.0 – 29.9 – Overweight;  >30 – Obese; 
>40 – Morbid obesity 
Among the addictions, cigarette smoking has been investigated world wide as a risk factor 
for coronary heart disease (CHD), along with high blood pressure and cholesterol disorders. 
The nicotine in cigarettes and other tobacco products cause blood vessels to constrict and 
heart to beat faster, which temporarily raises the blood pressure. Drinking alcohol 
excessively also is found to increase the frequency of high blood pressure by one and half to 
two times. Alcohol when present in the blood stream it covers the blood vessels and arterial 
walls increasing the tension and subsequently the blood pressure. In the recent past 
emphasis is laid on the use of balanced high blood pressure diet with sparse amounts of 
saturated and trans-fats and moderate amounts of other fats. Micronutrients are also as 
important since intake of increased amount of sodium and low levels of potassium and 
calcium in the diet lead to increases in blood pressure. Increase of potassium in diet helps to 
balance the amount of sodium in cell fluids and rids cells of excess sodium through kidneys, 
which filters out extra amount of sodium while inadequate potassium can allow excess 
sodium to accumulate and thus increases the blood pressure. High levels of intracellular 
calcium increases vascular smooth muscle tone, peripheral vascular resistance, and 
responsiveness to the sympathetic and RAS systems that elevate blood pressure. 
Paradoxically it is low not high calcium intake that stimulates an increase in parathyroid 
hormone which leads to calcium mobilization from the bone, increased intestinal calcium 
absorption, decreased renal calcium excretion, increased intracellular calcium concentration  
with increase in blood pressure. In general, life style factors like lack of exercise and physical 
activity, sedentary jobs, habit of smoking and consuming alcohol all are also associated with 
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enhancement in blood pressure and more so when the individuals are genetically 
predisposed to the condition. 
2.2 Genetic factors 
2.2.1 Inheritance of hypertension  
Inter individual variations in BP levels are known to be inherited with 30% of contribution 
although the exact genetic factors that contribute to the variations are not clearly established  
The concept of genetic basis for hypertension originated 50yrs back itself with the proposal 
of Platt (1967) who stated that essential hypertension arises due to a single dominant gene. 
He observed that blood pressure values among the sibs followed a bimodal distribution 
with two peaks corresponding to systolic blood pressure of 130 mm mercury inherited by 
the normal gene and those with 160 mm mercury inherited by the gene for hypertension. At 
the same time Pickering (1967) proposed his view that blood pressure is inherited as a 
multifactorial condition since the frequency distribution curves (bell shaped) for blood 
pressure in the relatives of patients were observed to be similar in shape to the distribution 
observed in the population based sample. The distribution however showed a shift upwards 
to one extreme or skewed by about the same amount at all ages. Further evidences for the 
possible involvement of genes for hypertension comes from the population studies 
exhibiting greater similarity in the measurement of blood pressure within families than 
between families (Longini et al, 1984). This familial resemblance appears to be present at all 
levels of blood pressure and hence same genes can be predicted to influence blood pressure 
over all values- the hypothesis proposed by Pickering.  Given an affected first-degree 
relative, the risk of hypertension is found to be increased 2-5 fold in family members as 
compared to the population risk. Studies conducted on familial aggregation of hypertension 
demonstrated correlation in the blood pressure levels between sibs and between parents and 
children (ranging from 0.14-0.18) and between monozygotic twins (ranging from 0.55-0.58) 
as opposed to dizygotic twins (ranging from 0.25-0.27) supporting the genetic basis for the 
condition. This observation is strengthened further by the presence of higher concordance 
rate among biological sibs as opposed to adopted siblings living in the same household 
(Mimura, 1973; Biron et al, 1976; Feinleib et al., 1977; Rice et al., 1989; Williams et al, 1991; 
Oscar et al., 2000). As family members share genes and environment, the correlations 
regarding blood pressure levels between them may also result due to interaction with 
shared environment. However, relatively low blood pressure correlations observed between 
pairs of spouse (0.06-0.08) implicate a substantial influence of genetic factors when family 
blood pressure correlations are considered. Furthermore, adoption studies indicated higher 
correlation in the levels of blood pressure between the parents and their biological children 
than between parents and their adopted children (Biron et al, 1976) emphasising genetic 
basis for blood pressure.  
The strength of a genetic component for a multifactorial condition like hypertension is 
estimated as heritability, which is defined as the proportion of phenotypic variance due to 
genetic factors over the total phenotypic variance observed. Heritability encompasses two 
genetic components causing effects that are a) Additive and b) Dominant effects. Narrow-
sense heritability, denoted as h2 reflects the additive genetic effects and is considered as a 
measure of predictability of offspring trait values based on parental trait values whereas 
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broad-sense heritability estimates denoted as H2 include dominant gene effects which 
explain part of the heritability resulting due to the effects of major genes. However, these 
major genes do not generally contribute substantially to the heritability of complex 
quantitative traits like blood pressure in the general population. Large family-based studies 
conducted have estimated 20-40% narrow-sense heritabilities for DBP and SBP (North et al, 
2003) and around 60% in twin studies (Williams et al, 1991).  
Effect of age was also demonstrated on the heritability estimates for blood pressure by the 
studies on adult twins which was higher than in case of infant twins (Scott et al, 2010). This 
suggests that blood pressure heritability increases with age. In general heritability of blood 
pressure attributed to all the genetic factors varies from 25% in pedigree studies to 65% in 
twin studies.  
2.2.2 Genetic determinants 
Genes responsible for hypertension in reality may be the ones that are meant to regulate 
blood pressure levels in an individual. Such genes are not likely to be the causative 
mutations, but they may be akin to "oncogenes" which are essential to life but may be 
getting abnormal in function at a given time. So the genes for hypertension are normal but 
impacted by the confounders raising the blood pressure level leading to clinical expression 
of the condition. Neel et al. (1998) rightly used the term “Syndromes of impaired genetic 
homeostasis” to diseases arising due to mismatching of previously adaptive genotypes and 
modern environmental conditions. In populations without any hypertensinogenic factors 
blood pressure measurements follow a normal distribution but will be skewed towards 
right of the curve with narrow base or less variance. With the addition of hypertensinogenic 
factors like insulin resistance, obesity, high sodium intake, circulating angiotensin levels etc.,  
the distribution may be skewed further to the right, with flatter curve and more variance 
indicating increase in the frequency of subjects with hypertension who get plotted under the 
tail end of the distribution (Oscar et al., 2000, Fig-2) The hypertensinogenic factors 
themselves may possibly have important genetic component and may act as intermediary 
phenotypes enhancing or decreasing the blood pressure levels like in case of obesity which 
is observed to be a  risk factor  for enhancing  blood pressure. Severe the obesity greater is 
the risk observed for developing hypertension. Concerning the molecular basis of essential 
hypertension, the focused view is that in populations blood pressure has a quasi-unimodal 
distribution and in a person with higher blood pressure values, higher are the chances of 
him possessing the disease-type variant alleles of the susceptibility causing gene. Thus 
greater number of susceptibility genes are likely to be impaired in hypertensives as 
compared to normotensives (Kato, 2002) (Fig-3).  
The advanced molecular biological technologies developed in the recent past helped in 
identifying as many as 17 independent mutations in genes associated with hypertension (8 
genes) or hypotension (9 genes) (Lifton et al., 2001; Table- 3). These monogenic Mendelian 
forms of hypertension are rare and arise mostly due to the errors in different metabolic 
pathways. Mechanism underlying these genes does not explain the blood pressure 
variability observed in populations (Staessen et al., 2003).  Hence efforts were focused more 
on the gene(s) and interacting confounding factors that influence the blood pressure 
variations leading to the clinical expression of essential hypertension. Several strategies 
were applied to meet this end which led to the consensus that hypertension is more likely a 
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Fig. 2. Hypothetical Curves of liability for BP in general population and relatives of 
Probands. A- Mean BP levels in population; B-Mean BP levels in relatives of probands. 
 
 
Fig. 3. Linear increase of BP levels with increasing variant alleles. 
cumulative burden of many genes with small effects. It is now accepted that hypertension is 
a multifactorial condition with the interplay of several genes with small effects. The search 
proved to be tough due to the realities like a) Lack of standardisation and arbitrary 
dichotomisation of a continuous variable into hypertensive and normotensive groups b) 
Requirement of very large sample sizes to obtain good statistical power c) Inappropriate 
selection of controls d) Population admixture and stratification e) Failure to account for 
confounders like environmental and epigenetic factors which themselves may be associated 
with independent genetic variants (like obesity, salt and potassium intake etc.), f) 
Assessment of the effects of environmental factors on genetic variants which develops over 
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time at different levels in different individuals and finally g) Presence of genetic 
heterogeneity where inter-individual variations in blood pressure levels are observed with 
reference to the associated genetic variants and also environmental factors which adds to the 
reduction in the power of the study considerably. Against all the odds, research on 
hypertension genetics has made remarkable progress in the last two decades towards better 
understanding of the condition mainly due to the development of wet lab technologies, 
biostatistical approaches for data analysis and bioinformatics tools.  
 
Syndrome Mutations In 
Mode of 
Inheritance 
Glucocorticoid remediable aidosteron 
ism (GRA) 
Chimerical gene containing 
promoter area of AS and 
coding region of 11ǃH  
Dominant 
Apparent mineralocorticoid excess 
(AME) 
Absence of 11ǃHSD  Recessive 
Liddle syndrome ǃ or Ǆ  subunit of ENaC  Dominant 
Pseudohypoaldosteronism type 2  One of the Genes mapped to 
1q31-42, 12p13 and 17p11-q21 
Dominant 
Hypertension induced by pregnancy Mineralocorticoid receptor  Dominant 
Hypertension with brachydactyly Gene mapped to 12p11.2-12.2 Dominant 
Defective aldosterone Aldosterone Synthase or 21 
hydroxylase 
Recessive 
Dominant Pseudohypoaldosteronism 
 type 1 (PHA1) 
Mineralocorticoid receptor Dominant 
Recessive Pseudohypoaldosteronism 
type 1 (PHA1) 
ǂ,ǃ or Ǆ subunit of ENac Recessive 
Peroxisome proliferators activated 
receptor gamma (PPARǄ) 
PPARǄ Dominant 
Gitelman’s syndrome Thiazide sensitive Nacl cotrans  
-porter 
Recessive 
Bartter’s syndrome Ion transporters  Recessive 
Table 3. Mendelian forms of blood pressure dysregulation. 
3. Methods for identifying genetic determinants 
Presently two major approaches viz., a) Association studies b) Linkage analysis are being 
adopted to identify the genetic components underlying complex diseases including essential 
hypertension. 
3.1 Association studies 
This approach is based on comparison of cases with controls to examine whether an allele or 
genotype of particular polymorphism (Table- 4) at candidate gene loci are seen more 
frequently in disease populations than in a control population. This approach requires 
careful selection of controls with adequate sample size that has statistical power to validate 
the results. The controls planned should match with the disease population for parameters 
like sex, age, ethnicity, socioeconomic status, accurate diagnosis etc. The controls should 
www.intechopen.com
 
Recent Trends in Hypertension Genetics Research 
 
109 
also be screened for the presence of hypertension and history of associated conditions like 
diabetes, thyroid disorders, cardiac disorder, stroke etc., (which may have genes 
overlapping with genes for hypertension) and should be drawn at random from the same 
population/ethnic group from where the patient group is selected. The controls drawn from 
the population are unrelated and thus expected to have random distribution of the marker 
alleles selected. For age related condition like hypertension which increases in frequency 
with age, one should be certain that the control subjects are not likely to be the carriers for 
the hypertension susceptible genes. It is rather difficult to achieve this requirement and one 
way of reducing the bias in selecting the controls will be to include such of the individuals 
who are older than the mean age of onset reported for the patient group and also subjects 
who do not have the family history of the condition. A better alternative choice of controls 
would be the unaffected normal sibs who are elder to the patients so that they would have 
crossed the age at expression of the condition in that family at the time of investigation. 
Further sibs share common environment and hence it would be possible to sort out the 
genetic component underlying the condition from the environmental factors. The careful 
selection of the controls can avoid the spurious conclusion on the associations found 
between the disease and the polymorphic loci.  
 
Type of Marker 
No. of 
Loci 
Features 
 
Blood Group antigens 
 
 
>25 
 
Genotype cannot always be inferred from the 
phenotypes. Difficult for physical localization 
 
Serum Proteins 
 
30 Often limited polymorphism. Difficult for physical 
localization 
 
Leaucocyte antigens (HLA) 1 
 
HLA system with A, B, C, D and DR loci each harboring 
hundreds of alleles thus resulting extensive 
polymorphism. Is  highly informative 
 
Restriction Fragment Length  
Polymorphisms (RFLPs) 
 
>105 Two allele markers, maximum heterozygosity 0.5, 
genotyped using Southern blotting and PCR techniques. 
Easy for physical localization 
 
Variable number of tandemn  
repeats (VNTRs) 
 
>104 Many alleles and highly informative. Easy for physical 
localization. Tend to cluster near the ends of 
chromosomes 
 
Microsatellites 
 
>105 Many alleles and highly informative.Easy for physical 
localization. Distributed throughout the genome 
 
Single Nucleotide Polymorp- 
hisms (SNPs) 
 
>4x105 Less informative than microsatellites. Can be genotyped 
on a very large scale using automated equipment 
 
Table 4. Polymorphic genetic markers used in genetic analysis and identification of disease 
genes. 
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Association studies rely on the phenomenon of linkage disequilibrium (LD) and are 
conducted to evaluate the risk for developing the disease by the individuals carrying a 
specific genotype or allele of polymorphic candidate loci. These loci when  co-dominant 
have three genotypes (AA, Aa and aa) determined by the combination of two alleles (A and 
a). In normal population the distribution of genotypes and the alleles are expected to be in 
“Hardy-Weinberg equilibrium” (HWE) and there may be deviations from the equilibrium 
when events of migration, genetic drift, selection etc., operate in a given population. 
Deviations in genotypic and allele frequencies of a marker gene from HWE in a patient 
population indicate possible association of the disease susceptible gene with the marker 
allele that may cause risk to the carrier individual of that allele for developing the condition.  
Linkage disequilibrium (LD) results when the frequency of one or more gametic 
combinations of alleles at two loci A and B does not coincide with the combined individual 
frequencies of the two alleles i.e. PA1B1 ≠   pA1pB1.  
In this context the term linkage does not refer exclusively to loci on the same chromosome, 
but it also includes loci on other chromosomes. Linkage disequilibrium (D) is measured as 
the product of frequency of gametes with the same type of alleles minus the product of the 
frequencies of gametes with different types of alleles  
       D= PA1B1 PA2B2 - PA1B2 PA2B1  
When D = +0.25, only gametes with same type of alleles A1B1 and A2B2 occur in a 
population. When D = 0, the two loci are considered to be in genetic equilibrium 
Lower the frequency of recombination between the loci, longer the time it takes for the 
genes to reach equilibrium. After several generations, the two genes do not reach 
equilibrium because of absence of crossing over due to absolute linkage between them. 
The significance of associations is judged by the values of “Odds Ratios” (ORs) computed 
by comparing patient and control groups for the frequencies of marker alleles/genotypes as 
a ratio. The ORs obtained for any allele/genotype is compared against a reference value of 
1.0, the ratio obtained when the distribution of genotypes of  a polymorphism remains more 
or less similar n both patient and control groups. OR’s can deviate significantly from 1.0 and 
when the OR is significantly >1.0, then the locus tested is considered to be in positive 
association with the disease, causing risk to the individuals carrying the particular 
genotype/allele; when it is significantly <1.0, it is interpreted that the marker allele is 
negatively associated and offers protection to the carrier individual against the disease. The 
ORs are computed for alleles (A vs. a) or for one genotype against any of the other two 
genotypes (AA vs. Aa; AA vs. aa and Aa vs. aa) and also for one genotype against the 
pooled frequencies of other two genotypes (AA vs. Aa + aa; Aa vs. AA + aa and aa vs. AA + 
Aa). These values are also represented as those obtained under “Dominant Model” [(which 
specifically tests the association of having at least one minor allele say ‘a’ (i.e. in Aa or aa 
individuals) versus not having it at all (AA individuals)] and “Recessive Model” [(which 
specifically tests the association of having the minor allele “a” in homozygous state (aa) 
versus having at least one major allele A (Aa or AA individuals)]. 
Odds Ratios are also computed to predict risk of alleles of individual markers and/or 
multiple markers. When multiple marker alleles are used to test associations, Bonferroni 
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corrections is applied to validate the significance of risk obtained for the individual markers 
studied. In addition, ORs can also be computed for haplotypes/haploblocks formed by a set 
of alleles of marker genes  on the same chromosome along with the disease gene. Haplotype 
associations provide information on the combinations of certain alleles present on the same 
chromosome as the disease gene. Associations of the disease gene found with certain 
haplotypes may enhance or circumvent the risk estimates obtained for single marker allele. 
The association detected can be positive or negative and the criteria required for high 
quality positive and negative case control studies are described by Sharma and Jeunemaitre 
(2000). The criteria suggested for  Positive case-control study are -  large sample size; well 
matched controls; accurate definition of the phenotype; a priori estimation of the power of 
the study; small p-values adjusted to the number of  SNPs tested; biological plausibility and 
functional significance; independent replication in several populations; confirmation in 
family based studies; high ORs/attributable risk and for a Negative case-control study these 
criteria are - large sample size; well matched controls; accurate definition of the phenotype; 
biological plausibility and functional significance; a priori estimation of the power of the 
study; testing at least three polymorphisms at the same locus; independent replication in at 
least one other populations; haplotype analysis.        
The positive associations of the marker alleles tested with the disease may result due to a) 
Functional relationship between the marker allele and the disease susceptibility genes b) 
Pleiotropic effect of the disease causing genes c) Epistatic (Non-allelic) interaction between 
marker alleles and disease causing genes d) Linkage disequilibrium between marker loci 
and disease causing loci e) Effect of natural selection. Absence of association may indicate 
no role of the markers studied in the causation of the disease. The finding could be a false 
negative resulting obviously due to lack of power and does not refute the hypothesis of 
association. It should be noted that there is strong inverse relationship between the 
frequency of a given allele in a population and the number of probands needed to test its 
contribution to the phenotype particularly with those with low heritability expected like in 
hypertension (Sharma and Jeunemaitre, 2000). Contribution of rare alleles cannot be ruled 
out because of lack of power. By increasing the sample size the contribution of rare alleles 
can be brought to light. Negative results found in a population/ethnic group need not 
replicate in other populations/ ethnic groups since in different populations different genetic 
variants may either cause risk  or protection to the condition. It is possible that in 
populations there may be more number of alleles causing susceptibility and less number of 
alleles counteracting the onset of hypertension. The analysis of intermediate demographic, 
biological or clinical phenotypes associated with hypertension also may help to subdivide 
the patient population into homogeneous groups and help in further analysis to achieve 
more precise results.  
Association studies in general are widely pursued because i) The study is easy to conduct 
based on cases and controls  since there is feasibility of collecting large number of samples 
from unrelated individuals without much difficulty, ii) It does no require any assumption 
about inheritance pattern,  iii) Statistical power of the study is relatively large with the 
requirement of 1,000 samples to detect the relative risk of 1.5 for a given genotype iv) 
Candidate genes can be selected for conducting the study based on the physiology and 
biochemistry related to the disease process v) Small chromosomal region ranging between 
3kb - 50kb in size is enough to detect linkage between the putative gene for the condition 
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and marker genes vi) About 100,000 SNPs are enough to conduct genome wide association 
scans (GWAS). The only disadvantage in the study is the possibility of obtaining false 
positives because of population stratification and heterogeneity of the condition. Population 
stratification can be resolved by studying additional polymorphic loci located on different 
chromosomal regions and verifying for differences in the allele frequencies in the 
population. Unaffected family members can be used as controls to avoid the contribution of 
associated confounding factors. Other limitations of an association study are, it cannot 
detect genetic linkage of loosely linked loci. Since the approach can detect linkage only 
when the polymorphism and the disease susceptible gene loci are in linkage disequilibrium, 
the study can be conducted only by using candidate genes rather than the anonymous DNA 
markers. It should be remembered that lack of linkage disequilibrium between the loci 
studied does not necessarily imply absence of linkage. When the marker and disease 
causing mutation loci are located several million base pairs away, the linkage can still be 
detected using more powerful techniques to analyse the data. 
3.2 Linkage analysis 
Linkage is a phenomenon that deals with the tendency of any two traits (phenotypes, 
marker alleles etc.) to co-segregate among family members of extended pedigrees because 
the loci that harbor these genes are physically located on the same chromosome with 
defined distance. The strength of the linkage depends on the distance between the two loci 
which is represented as Centi Morgan (cM).  cM is a unit that indicates the probability of 
recombination, consequence to the crossing over occurring between the two loci present on 
the same chromosome and is expressed as percentage. Greater the distance between the two 
loci, higher will be the frequency of crossing over leading to recombination occurring 
between the loci being tested. The analysis of linkage is carried out as a) Two point analysis 
where the distance between two loci i.e. disease causing locus and marker locus are assessed 
and b) Multipoint analysis where several loci presumably including the disease causing 
locus are tested for the distance between them. Multipoint linkage analysis helps to resolve 
the order of location of the candidate loci and the position of the disease causing locus in 
relation to them. It also identifies the candidate loci flanking the disease gene locus. Linkage 
between any two loci is computed as lod score based on which distance between any two 
loci can be determined that is expressed in terms of Centi Morgans or cM. Lod Score 
analysis can be i) parametric or ii) non-parametric. For parametric estimations a precise 
genetic model or inheritance pattern for the condition under study should be known along 
with the gene frequencies and penetrance of  the genotype of the markers studied. With 
valid model it stands as a powerful method to scan and localize Mendelian disease genes 
within 20-Mb segment of the chromosome. In contrast, nonparametric method is applicable 
for conditions for which precise inheritance pattern can not be assigned like in hypertension. 
It is also referred as “model free” method and depends on identifying the alleles or 
chromosomal segments that are shared by affected individuals in a given family or 
population, resulting in resemblance/concordance for the two traits being studied. 
3.2.1 Parametric method  
Parametric method is applied for  localizing/mapping genes for the condition with definite 
model of inheritance. For the mapping of gene(s) for an autosomal dominant condition, 
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conventional method of Linkage analysis is carried out based on the estimation of likelihood 
of the genetic marker loci (Table -4) which are polymorphic with high heterozygosity that 
co-segregate along with disease among the family members through generations. It is based 
on the estimation of Lod score (L) that is defined as the likelihood of obtaining a 
family/pedigree with the segregation of marker and disease loci together in the presence of 
certain amount of recombination between them (depicted as θ or x or r) and which varies 
from 0.0-0.5) compared to the likelihood of obtaining the same family/pedigree when there 
is no recombination between the marker and disease loci ( i.e. θ or x or r = 0.5) i.e. when the 
recombination frequency between the two loci is maximum which means that there is 
absence of linkage  
Maximum likelihood estimate (mle) of recombination fraction (referred as θ or x or r) is 
used for determining linkage between two loci on a chromosome based on the relative 
probability (PR) of having obtained the family. The PR is determined by calculating the 
probability of having obtained the various combinations of the particular trait under 
consideration on the assumption of there being no measurable linkage (H0= No linkage; θ = 
0.5) and comparing this with the probabilities based on a range of recombination fractions θ 
varying from 0.00 to 0.05, i.e. 
  
 
 R 
P FAMILY,  GIVEN   0.0 to 0.5
P
P FAMILY,  GIVEN   0.0 to 0.5




PR   is expressed as its logarithm. The log10 of PR is called as log of the odds or lod score. 
Lod score value of ≥ 3.0 indicates that the two loci tested are linked, value of 2.0 as evidence 
of strong linkage, value of 1.0 as evidence for tentative linkage and that of -2.0 absence of 
linkage. The Lod score of 2.0 that is suggestive of linkage can be further evaluated by 
analyzing more candidate/marker loci and by screening additional members of the family. 
Large extended pedigrees with valid power are required for linkage estimations and gene 
mapping of an autosomal dominant condition. Extent of penetrance and population 
frequency of the gene in question and information on phase of linkage are required while 
using this method. 
For an autosomal recessive condition where the parents of the affected individual are 
invariably blood relatives and heterozygous, different approach is adopted. It is ascertained 
whether both the alleles in the homozygous affected inbred individual are demonstrably 
transmitted representing copies of an allele present in a common recent ancestor. Such 
alleles in the homozygotes are referred as “Identical by descent” or as IBD. When the 
alleles carried by an individual are identical, but are not demonstrably inherited from the 
common ancestor implying that they have two different origins, then they are referred as 
“Identical by state” or as IBS (Fig- 4). Hence IBS analysis is based on population 
frequencies and not on Mendelian probabilities. The inbred individual is expected to be 
homozygous for the segment of the chromosome with some loci flanking to the disease 
causing locus. By examining the segregation of such flanking loci (haplotypes) from the 
phenotypically normal but heterozygous parents to the affected offspring, one can estimate 
whether the disease causing locus and the candidate loci are linked based on the extent of 
recombination occurring between the loci studied. For linkage analysis of an autosomal 
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recessive condition less than 10 pedigrees with the affected offspring and parents are 
considered adequate. There is no need to have information on the extended pedigrees. This 
method is useful for identifying genes for rare autosomal recessive conditions where the 
parents are invariably blood relatives/cousins and hence have higher chance of inheriting 
same mutant allele from the common ancestor. Also the method is suitable to study the 
small families with affected children but phenotypically normal parents who could be the 
founder members in small communities. For very rare alleles, two independent origins of 
alleles in the homozygotes are unlikely and hence IBS will become similar to IBD. This is 
unlikely with common alleles where there is possibility of having identical genes in the 
homozygote individual that are not IBD in origin. For IBD analysis multiple loci with 
multiple alleles logically will yield better results. Both IBD and IBS methods can be used to 
estimate linkage by examining the shared chromosomal segments or alleles for nuclear 
families (sib-pair studies for concordance/resemblance for the two loci) or in the whole 
population descending from FOUNDER population.  IBD method of analysis is more 
powerful but the study has to be conducted using large number of affected relatives 
specially the parents.  
 
a. Identity by State for allele 1 b. Identity by Descent for allele 1 
Fig. 4. Pedigrees showing transmission of alleles that are identical by state (IBS) and 
identical by descent (IBD). 
3.2.2 Non-parametric or model free method 
3.2.2.1 Linkage disequilibrium (LD) mapping 
Linkage disequilibrium may result due to a mutation in individual/individuals in the 
world population at some point in human history. These mutations would have 
segregated in the following generations along with the neighboring loci on the affected 
chromosome. In successive generations the recombination events scramble the alleles of 
the loci surrounding the disease causing gene. After several generations, the disease genes 
and the loci that are closely linked with it from the original chromosome remain together 
with no chances of further recombination between them. As a result the frequency of the 
two linked genes exceeds or will be in disequilibrium with that predicted by multiplying 
together their individual frequencies. This phenomenon referred as linkage 
1 2
1 21 3
1 3 1 2
1 41 3
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disequilibrium (LD) is defined as non-random association of alleles at two or more loci 
present on the same or different chromosomes. The region of the chromosome with 
disease and linked neighbouring loci form a part of the unique haplotype on the ancestral 
chromosomal fragment and such segments help in mapping the genes more precisely for 
monogenic or multifactorial conditions. The distance between the loci mapped through 
LD estimations is often less than 1-2 cM, lower limit that can be resolved by conventional 
genetic linkage studies. Now several free soft wares like Haploview, PLINK, Gene hunter 
etc., are available to evaluate the level of LD, haplotype associations with disease causing 
genes, LD mapping, etc.,  
LD mapping can be extended to nuclear families by performing “Transmission 
Disequilibrium Test” (TDT). 
Transmission disequilibrium Test (TDT), is a family-based study to test whether a marker is 
associated with the disease. Families with parents and one or more children are used for the 
test. It is irrelevant if either parent is affected. or not. For this test parents who are 
heterozygotes for the marker allele are selected and number of offspring with the allele 
transmitted are compared with those without the transmission. The test is not affected by 
opulation stratification. An extended TDT test, ETDT is developed to handle data from 
multiallelic markers like microsatellites. The test can be applied when only one parent is 
available but the results may be biased. When both the parents are not available, sib-TDT 
can be applied. The test involves genotyping of the probands and their parents and selection 
of heterozygous parents (they may or may not be affected). If “a” is the frequency with 
which a heterozygous parent transmits the marker X1 to the affected offspring and “b” is the 
frequency with which the other allele X2 is transmitted, then TDT is tested by the statistic 
which follows chi-square distribution with 1 degree of freedom                
 χ2  =  (a-b)2  ⁄  (a+b)  
3.2.3 Sib pair method 
Identifying disease genes for hypertension following conventional Lod Score method is not 
possible because recombination events cannot be detected and mode of inheritance can not 
be easily modeled. Further the condition is age dependent and often parents of the patients 
will not be available for evaluation. Information on the offspring of the patients is also not  
useful as they would not have reached the mean age of expression of the condition in a 
given family and also the population from where the patients are drawn. Hence the family 
studies will have to be horizontal since reliable information about the disease can be 
obtained only from the sibs of the affected who will also be available for clinical and 
laboratory investigations. 
Sib-pair analysis which is based on concordance or co-occurrence of marker alleles and 
disease susceptibility gene among pairs of sibs in multiple families is considered to be a 
more powerful method when compared to association studies as it does not depend on 
phenomenon of LD as is the case in the latter. It is a robust test for linkage analysis 
particularly when the inheritance model cannot be predicted. For any given locus parents 
carry four distinguishable alleles whose transmittance to the offspring can be traced. The sib 
pairs can be grouped into four categories where pairs may inherit both, one or none (2, 1, 0) 
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of the alleles from the parents with the probability of 25%, 50% and 25%  (expected ratio of  
1:2:1, Fig-5). 
 
Fig. 5. Pedigree showing allele sharing between the sib pairs. Numbers in parenthesis 
denote the expected number of alleles shared by the sibs under Mendelian segregation. 
If both the sibs in a pair are affected with a genetic disease then they are expected to share 
segment of the chromosome carrying disease locus. Affected sib pairs (ASP) are genotyped 
for the selected markers, and chromosomal region is searched where sharing by the sibs is 
above the expected 1:2:1 ratios of sharing 2, 1, and 0 alleles that are IBD. If the sib pairs are 
tested for IBS, the deviation from expected 1:2:1 ratio should be based on population 
frequencies. ASP analysis is a preferred method for studying conditions like hypertension 
since it is easy to identify and collect the sib pairs than the affected families and the analysis 
is model free. Multipoint analysis rather than the single point analysis is preferred since it 
offers opportunity to extract IBD information about alleles on the shared chromosomal 
segment (haplotypes) more efficiently. The lod scores computed in ASP analysis is indicated 
as NPL scores. The chromosomal segment identified by ASP analysis is usually large and 
not feasible for positional cloning. Yet the method stands as a main tool to search for the 
susceptibility genes for common non-Mendelian diseases like hypertension in view of its 
simple approach and robustness.  
3.3 Epistatic interaction 
Identification of interaction between genes and genes and environmental factors in 
explaining complexity of human diseases has been challenging. There is increasing evidence 
that epistasis or gene-gene (non-allelic) interactions play an important role in determining 
an individual’s risk for developing complex diseases like hypertension (Williams teal, 2000; 
Tsai et al., 2003). New tools are developed to detect such synergistic interaction between 
alleles/genes arising due to epistatic phenomenon and modification of phenotypes like 
gradation in severity etc., due to additive effects or simple correlations between them. One 
such tool that is being used in interpreting the results for conditions like hypertension is 
“multifactor dimensionality reduction (MDR) analysis” - a nonparametric, model-free test 
alternative to logistic regression for detecting and characterizing nonlinear interactions 
among discrete genetic and environmental attributes. 
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MDR method combines attribute selection, attribute construction, classification, cross-
validation and visualization to provide a comprehensive and powerful data mining 
approach to detect, characterize and interpret nonlinear interactions. The method is effective 
in detecting multilocus interactions among different polymorphisms of many different 
genes. It is a data reduction strategy (Ritchie et al, 2001) and in this model multilocus 
genotypes are pooled into high risk and low risk groups, effectively reducing the 
dimensionality of the genotype predictors from N dimensions to one dimension. The new 
one-dimensional multilocus genotype variable is evaluated for its ability to classify and 
predict disease status using cross-validation and permutation testing. MDR is advantageous 
program as it identifies evidence for high-order gene–gene interactions in the absence of any 
statistically significant independent main effects in simulated data (Ritchie et al, 2003).  
4. Strategies 
Several strategies are being used while searching for the genes causing susceptibility to 
essential hypertension such as  i) Candidate gene approach, ii) Use of intermediary 
phenotypes, iii) Genome wide Association scans (GWAS) ,.iv) Animal models.  Combination 
of two or more of these methods is also used. 
4.1 Candidate gene approach 
Candidate genes are defined as the genes that might be responsible for the onset of an 
inherited disorder. They are identified without reference to their chromosomal location. 
First a candidate chromosomal region is identified by linkage studies etc., and then the 
candidate genes from within the chromosomal region by verifying from the list of human 
genes available on the websites (NCBI; HuGe Literature Finder). From among the possible 
candidate genes thus identified, the one that is likely to be involved in biochemical, cellular 
or physiological functions contributing to the disease process are screened for mutation(s) 
that are likely to affect the structure, expression or function of the protein(s) associated with 
the disease development. The potential role of the candidate genes can be examined by 
using the methodologies adopted for linkage and association studies.  
Now more than 350 candidate genes have been implicated for hypertension that involves 
several different biochemical pathways (HuGE Literature Finder). Candidate genes for 
hypertension are selected logically based on already established effect on cardiovascular 
and renal function and on the basis of known pathophysiology of hypertension. Genes for 
monogenic forms of hypertension identified by molecular pathology for cases mentioned in 
Table-3 also act as candidates to study essential hypertension. A variety of candidate genes 
have been identified for essential hypertension that are related to the RAAS pathway, 
sodium epithelial channel, adrenergic function, renal kallikrein-kinin system, alpha 
adducin, endothelial dysfunction, lipoprotein metabolism, hormone receptors, growth 
factors and many more (Table - 5).  
Several studies from different ethnic groups demonstrated association of the potent 
candidate genes with essential hypertension that showed positive and negative results. 
These studies could not be replicated in different populations and the reason for the 
inconsistency in the results is mainly attributed to the heterogeneity in the samples studied 
leading to type 1 (false positive) and type 2 (false negative) errors. Lack of statistical power 
due to small samples screened and use of  improper controls are among the other reasons. 
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Table 5. (contd.) Some of the candidate genes reported with positive association for essential 
hypertension. 
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Selection of wrong candidate genes, location of the causative genes upstream or 
downstream from the candidate genes studied and discovery of new pathways for which 
candidates are not yet identified also contribute to the lack of success in some of the studies 
conducted. 
4.1.1 Candidate genes associated with essential hypertension 
Table -5 depicts some of the positive associations reported between essential hypertension 
and polymorphic candidate genes related to various pathways.  
RAAS Pathway: The RAAS is an important regulator of cardiovascular function and blood 
pressure (Soldner et al, 1996; Ferrario et al, 2006). It consists mainly of 4 genes including 
renin (REN) that converts angiotensinogen (AGT) to angiotensin I which is metabolized by 
angiotensin-converting enzyme (ACE)  to form angiotensin II, which can act on angiotensin 
II type 1 receptors (AGTR1) to mediate blood pressure elevations by mechanisms including 
direct effects on vascular tone and indirect effects via alterations of renal function. Thus 
REN, AGT, ACE and AGTR1 act synergistically on the phenotype of blood pressure. Each of 
the corresponding genes has several polymorphisms that can be associated with altered 
expression or function of the corresponding gene product. While each of these 
polymorphisms may potentially affect the regulation of blood pressure, most studies have 
focused on only few polymorphisms in each of these genes i.e., M235T, -217G>A, T174M, -
20A>C of the AGT gene, an insertion deletion polymorphism involving 287bp in intron 16 of 
the ACE gene and the 1166A>G in the 3’ untranslated part of the AGTR1 gene.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The 235T allele of the AGT gene is associated with a step wise increasing level of circulating 
angiotensinogen (gene dose response; Sethi et al, 2003). The positive correlation between 
polymorphism M235T and AGT plasma concentration has been observed in different 
populations (Mettimano et al, 2001; Agachan et al, 2003; Yan et al, 2006). Allele AGT*235T 
shows linkage disequilibrium with a variant in the AGT-gene promoting area – a 
replacement of adenine by guanine in nucleotide 6 (-6A>G). It has been suggested that such 
mutation -6A>G interferes in the interaction of transcriptor factors with AGT promoter, thus 
influencing the gene transcription baseline rate. An increase in AGT gene expression may 
increase the production of angiotensin II by RAAS, thus resulting in the expansion of blood 
volume, which in turn would increase blood pressure. AGT gene is primarily expressed in 
the liver and adipose tissue, and C/EBPs family transcription factors play a crucial role in 
regulating expression of a number of genes in these tissues. A study conducted by Sudhir et 
al (2002) showed that recombinant glucocorticoid receptor (GR) and C/EBP family 
transcription factors bind strongly to nucleoside A compared with nucleoside G at -217 
position of AGT promoter region resulting in increased transcriptional activity of -217A 
allele which may be involved in essential hypertension. Further, -20A>C located between 
the TATA box and the transcription initiation site is thought to modulate gene expression in 
a gender specific manner (Zhao et al, 1999). Tomoaki  et al (1997) demonstrated that plasma 
angiotensinogen levels increase linearly with the number of -20C allele and that the subjects 
with the CC genotype are associated with the highest plasma levels of AGT. In in-vitro 
studies by Zhao et al (1999) the A-20C polymorphism has been found to influence basal 
transcription of angiotensinogen as well as stimulate transcription in response to receptor 
binding. 
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ACE insertion/deletion polymorphism was characterized in 1990 and studies have 
suggested that this polymorphism interferes in ACE serum concentration. DD Genotype 
individuals would have the highest ACE serum concentrations (Sayed et al, 2004; Mondry et 
al, 2005) and it is estimated that allele D would contribute with approximately half the 
variation of ACE plasma levels (O’Donnell et al, 1998). Significant gender differences were 
also reported in ACE I/D polymorphism. Compared with the II genotype, DD 
homozygosity was associated with higher risk of hypertension in studies conducted on 
women (Gu et al, 1994; Kiema et al, 1996; Sipahi et al, 2006) whereas two other population 
studies (O’Donnell et al, 1998, Higaki et al, 2000) found that the D allele was significantly 
associated with hypertension in men but not in women. 
1166A>C at position 1166 in the 3’ untranslated (UTR) region of the AGTR1 gene was 
identified and was significantly shown to be associated with hypertension  by Bonnardeux 
et al (1994). However it is not clear whether this polymorphism alters mRNA 
polyadenylation or destabilization signal. It is possible that this polymorphism may be in 
LD with a functional variant located elsewhere in the AGTR1 gene or within a nearby gene 
that could explain the observed associations of this variant with cardio vascular phenotypes 
(Abdollahi et al, 2005). Therefore, this suppression may lead to the loss of cellular 
capabilities which protect against an excessive angiotensin II action (Grzegorz et al, 2002).  
The renin-angiotensin system thus plays an important role in the inter-related hormonal 
mechanisms that regulate blood pressure and electrolyte/blood volume homeostasis. The 
RAS is activated when there is loss of blood volume or drop in blood pressure (such as in a 
hemorrhage) or low concentration of sodium in plasma, whereas factors that increase these 
parameters tend to suppress its function.  
Sympathetic Nervous System: The sympathetic nervous system has also been implicated in 
the cardiovascular physiology and hypertension. The sympathetic nervous system primarily 
regulates the cardiovascular physiology by the release of catecholamines and activation of 
adrenergic receptors (AR). The human 2B-adrenoceptor is encoded by the ADRA2B gene 
located on chromosome 2q12 (Regan et al. 1988).  A common variant form of the this gene 
which encodes a receptor protein with a insertion/deletion (I/D) of three glutamate 
residues located in the third intracellular loop of the receptor has been associated with EHT 
(Lockette et al.1995; Wowern et al. 2004). 
Endothelial Dysfunction: Of the substances exerting their effect on vascular endothelium, 
Endothelial Nitric Oxide Synthase (NOS3) and Endothelin 1 (END-1) play an important 
role in regulating vascular tone. NOS3 gene synthesizes Nitric Oxide (NO), which is a 
potent vasodilator and the END-1 gene product acts as a strong vasoconstrictor called 
endothelin.  Endothelin exerts its physiological functions via its receptors on the vascular 
smooth muscle cells (VSMC), by activating cascade of intracellular molecules that increase 
the calcium ion concentration, resulting in vasoconstriction. However, NO lowers these 
calcium ions to basal level, to relax the constricted VSMC, resulting in vasodilation. Thus, 
the delicate balance between the NO and endothelin is required for smooth functioning of 
vascular tone. Generation of reactive oxygen species (ROS), from various metabolic 
pathways, scavenge the NO, reducing the NO bioavailability leading to endothelial 
dysfunction. Polymorphisms in NOS3 and END-1 genes have been associated with 
hypertension in some populations. 
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Lipid Metabolism: Essential Hypertension has been frequently associated with serum lipid 
abnormalities. This suggests that there may be common underlying genetic determinants 
between blood pressure regulation and lipid metabolism. Membrane ion transport, which 
has been related to hypertension can be altered by lipid abnormalities and could have some 
involvement in the mechanisms that link high triglyceride concentrations and hypertension. 
LPL is thought to function as a "gate keeper" for fatty acid (FA) uptake into organs 
(Greenwood, 1985); however, patients with LPL deficiency have no obvious defect in 
adipose tissue. To date, only a few studies have explored the relation between the genetic 
variants near or in the LPL gene and blood pressure variation. Positive linkage or association 
has been described in some studies, which indicate that the LPL gene may be an important 
candidate for affecting the risk of Essential Hypertension or BP variation (Sass et al 2000; 
Pan et al 2000; Wu et al 1996; Chu et al, 2001).  
Ion Transporters: G-Proteins are expressed in all cells of the human body and their main 
role is to translate signals from the cell surface into a cellular response. Polymorphisms in 
gene coding for G-protein subunits are expected to have a significant effect on the 
cardiovascular system. Hence, studying the genetic polymorphisms of the components of 
this system might give a new insight into the genetics of hypertension and may suggest 
novel downstream targets for therapy. 
In addition to the above, a number of other candidate genes have been investigated as 
contributing to hypertension in case control studies including those involved in renal 
kallikrein-kinin system, growth factors (TGF-ǃ), cytoskeletal proteins (alpha adducin), 
harmone receptors (PNMT1) etc., 
4.2 Intermediate phenotypes 
Difficulties were observed in conducting linkage studies for hypertension using 
multigeneration families mainly due to the heterogeneity factor, lack of clear cut 
inheritance model and substantial environmental influence. It is now understood that 
“intermediate phenotypes” may help resolving this problem to certain extent (Dudley et 
al, 1992). It is based on the view that the individual genetic determinants having specific 
biochemical, physiological, demographic phenotype may contribute to the increase in 
blood pressure levels leading to hypertensive state. These phenotypes determined by 
single genetic loci, segregate in families following Mendelian inheritance. Such families 
showing intermediate phenotypes can be identified and the locus causing the phenotype 
may be detected.  Since intermediate phenotypes are directly determined by the action of 
a particular gene, the influence of environment will also be less as compared to complex 
conditions like hypertension. Use of such phenotypes with greater heritability and early 
penetrance, have several advantages over the use of blood pressure phenotype as such. It 
helps, in identifying homogeneous group among the heterogeneous patient population 
like in hypertension. It also enables selection of large samples because even younger 
patients who are still normotensive can be identified with genetic risk for hypertension in 
the preclinical stage itself and this information will be useful for genetic analyses and at 
arriving better conclusions. In addition, it enables mapping of quantitative traits loci 
(QTL) in sibling pairs simultaneously testing for intermediate phenotypes. This approach 
is expanded to accommodate nuclear families of any size and also Transmission 
Disequilibrium Test (TDT; Timberlake et al., 2001).  Ideal intermediate phenotype is 
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suggested by these authors to have the features like - an association with essential 
hypertension; high heritability; high penetrance; early onset among offspring of affected 
parents; a bimodal distribution; causal role in the pathogenesis of elevated blood 
pressure; should suggest the candidate genes for testing hypertension. Further the 
intermediate phenotypes should be easier to genotype by noninvasive methods to test the 
relatives of the probands since invasive tests might deter the relatives from participating 
in the study.  
One of the simple and measurable intermediate phenotype that enhances the blood pressure 
to the level of clinical expression of hypertension is obesity/overweight. Obesity is 
considered as an hypertensinogenic factor that causes elevation in blood pressure leading to 
greater skewness in the normal distribution curve of blood pressure levels (Fig-2). So 
individuals with obesity, especially morbid obesity can be considered as those at higher risk 
for hypertension. In other words obesity can be considered as one of the preclinical 
symptoms for essential hypertension.  
Williams et al., (1992) described a phenotype called “non-modulation” characterized by 
non-modulation of aldosterone secretion and renal blood flow by angiotensin II infusion in 
a subset of hypertensive patients. i.e. the response is blunted to angiotensin II infusion. This 
parameter can be used to identify subjects at risk for developing hypertension in the 
patients at later years. Among other examples of intermediate phenotype useful for 
identifying candidates for screening for hypertension include M235T polymorphism located 
in exon 2 of AGT gene. The substitution of Methionine by Threonine at 235 position of the 
gene has been associated with increased levels of angiotensin in circulation leading to 
vasoconstriction and high blood pressure (Hopkins et al., 1996). Age, gender and interaction 
between genotypes have been described to contribute to this trait (Williams et al., 1992). In 
another instance cases with salt resistant hypertension have been associated with increased 
levels of urinary free cortisol with bimodal distribution and is considered to identify the 
new subset among hypertensives (Litchfield et al., 1998). Similarly urinary excretion of 
kallikrein which is an index of renal tissue expression of kallikrein has been associated with 
salt sensitive hypertension and hence can be used as intermediate phenotype for screening 
for essential hypertension specially in African-Americans (David et al., 2001). Other 
promising intermediate phenotypes are related to physiology and biochemistry of 
autonomic and sympathetic nervous system functions that can identify several subsets of 
hypertensive patients. In the following years list of intermediate phenotypes is expected to 
emerge that can be used successfully in linkage and association studies and would help in 
better understanding of mechanism underlying hypertension apart from resolving 
heterogeneity related with the condition. 
4.3 Genome Wide Scans (GWS) 
Since no single gene is solely responsible for the development of hypertension and it is 
tedious to study all the 350 implicated genes one by one for their causal role, genome wide 
scans (GWS) are attempted to identify susceptible regions on chromosomes comparing 
microsatellites/SNP variations that are spaced at regular intervals of 10-30 cM across the 
genome among large number of patients with appropriate controls and through linkage 
analysis, mapping and genome wide association studies (GWAS). These regions then can be 
searched for positional candidate genes and possible mutations in them, to conclude on the 
mechanism of the disease process and explore better management measures. 
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Genome wide scanning (GWS) is an indirect strategy in which affected individuals, siblings 
or family members with more than two affected individuals are genotyped for a number of 
polymorphic DNA markers (short tandem repeats and  simple sequence repeats) covering 
the entire chromosomal complement/genome. A set of bout 300-400 short tandem 
polymorphic repeats that are spaced for every 10cM is used in most genome scans. This 
covers approximately 3000 cM of the human genome. Later simple sequence repeats or 
microsatellites with an assembly of 3000 markers that are spaced with a distance of 1.5 cM 
were used to obtain better resolution of the genome map. Further resolution was achieved 
with the discovery of single nucleotide polymorphisms (SNPs) that are distributed for every 
300 bases in the genome. They are ~4x106 in number and are easily identified with 
automated sequencing and other techniques like restriction fragment length polymorphisms 
(RFLPs). Being more stable and non-mutable, screening for SNPs as markers is now pursued 
in genome scan attempts to detect linkage by LD mapping between marker loci and 
quantitative trait locus (QTL) like hypertension. Significance of the results obtained is 
determined based on the lod scores plotted as a function of the location in cMs along the 
genome. Generally lod score value of ≥3.6 is considered significant indicating presence of 
linkage while a value of >2.2 is considered suggestive and the value >1.5 is considered as 
interesting. Additional polymorphic markers and inclusion of more number of patient 
samples and family members can improve the lod scores obtained and reduce the events of 
false negative results.  
In human genome there are regions of high LD occurring as blocks ranging from 10 to 
>100kb separated by regions of little or no disequilibrium. Each block with high LD 
comprises small number of haplotypes and study of these haplotypes or haploblocks 
reduces the number of SNP markers to be screened to detect linkage or association with the 
disease gene with required precision and resolution. SNPs can be selected from 
International HapMap Project – a global consortium that has the information on all common 
SNPs recorded from different populations across the world. Through the genome wide 
association scan (GWAS) approach, SNPs from this project are selected to study the 
common diseases and traits based on “common disease common variant” (CDCV) 
hypothesis (Doris, 2002). In GWAS approach no assumptions are made about the location or 
function of the variant. Now genotyping micro chips with thousands of SNPs are available 
that offer much better coverage of human genome. Depending on the population/ethnic 
group studied relevant informative SNPs/tag SNPs from within or outside the genes can be 
selected and the GWAS can be conducted using ≥300,000 SNPs. 
GWAS scan the genome for association signal without selecting for gene regions. Gene-
centric approach to GWAS was proposed by Jorgenson and Witte (2006) since genic variants 
are more likely to be functionally important than nongenic variants. Further, variants in 
many genes are in low LD than those outside genes and hence may be difficult to capture by 
indirect association. Therefore instead of focusing on the whole genome, concentrating on 
the genic regions alone can provide increased coverage of the genes and also reduce the 
number of genotyping and burden on cost and time. The genic approach has greater power 
to detect variants within the genes when it suffers power for non-genic variants. Using 
HapMap data Jorgenson and Witte (2006) could demonstrate that it is more efficient in 
detecting causal variants than when whole genome approach is adopted. They suggest that 
combination of indirect genotyping data with gene based SNPs in high priority region 
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would be the best overall GWAS strategy. Alternate approach would be to use stringent LD 
threshold in genic regions to overcapture these regions. 
The major limitation of GWAS study is the high expenditure involved to screen very large 
sample sizes, for getting small effects. A new approach to reduce the cost of GWAS is to 
conduct the study in stages/phases. In phase I a proportion of samples are genotyped for all 
the markers and then in phase II a proportion of these markers are genotyped in the 
remaining samples (Skol et al., 2007; Hastie et al., 2010).  
The major issue in the study design of GWAS strategy is about the significance threshold. 
The conventional statistical significance determined using P-value threshold of 0.05 is not 
appropriate for GWAS because large number of tests performed increases the chance of type 
I error. Risch and Merikanga (1996) proposed new threshold levels now widely adopted 
which states that P <5 x 108 which corresponds to equivalent false positive rate of  5% for 
1000 000 independent tests of  association. The significance of the results can be tested using 
Bonferroni correction i.e. by dividing 0.05 threshold by the number of tests performed. 
Other issues are concerned to the evaluation of statistical power of the samples to obtain 
valid conclusion and resolution of problems related to population stratifications.   
Initial studies of GWAS have reported positive results with identification of chromosomal 
regions harboring disease susceptible genes but they failed to replicate in other studies 
because of overestimate of effective size. Other reasons were technical errors, small sample 
sizes, poor choice of controls and population stratification leading to type I error or false 
positives. These defects are rectified to certain extent using relevant corrections. National 
Cancer Institute and National Human Genome Research Institute Working Group on 
Replication in Association Studies recommended the criteria for replication. More number 
of GWAS are performed in the past decade identifying susceptible regions on the human 
chromosomes for essential hypertension. 
GWAS case-control study designs may not detect the rare variants causing blood pressure 
variations. From 1000 genome project - an open resource catalogue of human genetic 
variation run by international consortium intensely genotyped samples that can be obtained 
to study low frequency or rare variants for fine mapping of the regions of interest. The 
project aims to describe over 90% of genetic variation down to 1% minor allele frequency 
(MAF). Next generation deep sequencing technology also facilitates the detection of rare 
variants needed for fine mapping. 
4.3.1 Genome wide scans for hypertension 
Attempts to map the genes for hypertension picked in 1990s, initially based on the study of 
sib-pairs, affected families and by genome wide scanning for identifying the susceptible 
regions. One of the earliest studies by Lifton et al. (1991) reported that mean allele sharing at 
the locus of sodium-hydrogen antiporter (APNH) was not greater than expected from 
random assortment in 93 hypertensive sib pairs.  
Wellcome Trust Case Control Consortium (WTCCC), Control for Heart and Aging Research 
in Genome Epidemiology (CHARGE), Family Blood Pressure Programme (FBPP), British 
Genetics of Hypertension (BRIGHT), Global Blood Pressure Genetics (Global BPgen), Amish 
Family Diabetes Study (AFDS) all have reported genome wide scans results on variants 
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associated with variations in blood pressure and development of hypertension. Many of the 
initial studies could not meet the significance threshold criteria and in some chromosomal 
regions linkage were suggested.  WTCCC reported the first genome-wide association scan 
results that captured 65 variants on 2000 hypertensives from unrelated participants of 
BRIGHT study (Caulfield et al., 2003). However the study did not reach the required 
statistical significance (5 x 107) for hypertension and it was thought to be due to use of 
improper controls and inclusion of less number of tagged variants with large size effect 
(Barret et al., 2006; Padmanabhan et al., 2008). FBPP comprising four multi-centre network 
(GENOA, GenNet, HyperGen, SAPPHIRe) conducted studies on different ethnic groups 
with different selection criteria. None of the four centers reported significant results of the 
genome scan and the maximum lod score obtained was 2.96 showing linkage to diastolic 
blood pressure on the region of chromosome 1 in Caucasians (Thiel et al., 2003). BRIGHT 
study (Caulfield et al., 2003) with largest homogeneous Caucasian resource with 2010 
sibling pairs in 1599 families found by locus counting method a principle locus for 
hypertension on 6q with lod score of 3.21 that attained genome wide significance and also 
evidence of linkage for three other loci located on 2q, 5q an 9q. These regions did not 
overlap with that reported in FBPP study. Xu et al, (1999) using 367 polymorphic markers 
studied 200,000 Chinese adults comprising sib-pairs (207 concordant, 258 high concordant 
and low concordant and parents) and showed  that though no regions achieved 5% genome 
wide significance level, regions of chromosomes 3, 11, 15, 16 and 17 were linked with lod 
scores of >2.0. In their study on systolic blood pressure of 427 sibling pairs Krushkal et al., 
(1999) identified four regions on chromosome 2, 5, 6 and 15 with significant linkage. These 
regions include many potential candidate genes like phospholamban, dopamine receptor 
Type1A, Estrogen receptor calmodulin, sodium calcium exchanger etc. Pankaj Sharma et al, 
(2000) from a genome wide study identified the region on chromosome 11 to carry a new 
candidate gene for hypertension and suggested the need for replication of these results 
before attempting for positional cloning. Genome scan for blood pressure in Dutch 
dyslipidemic families (Hooman Allayee et al, 2001) showed suggestive evidence for linkage 
of diastolic BP to lipoprotein lipase gene locus on chromosome 8p. They also found evidence 
for linkage of systolic blood pressure to plasma apolipoprotein B levels to a locus on 
proximal chromosome 19p. Using 904 microsatellite markers, Kristjansson et al., (2002) 
reported linkage to chromosme18q with an allele sharing lod score of 4.60 in 490 
hypertensive patients belonging to 120 extended Icelandic families. Rice et al., in the same 
year performed genome GWS using 509 markers on 317 black individuals from 114 families 
and 519 white individuals from 99 families that revealed evidence for linkage (p<0.0023) 
with base line blood pressure that replicated with other studies that located putative regions 
on 2p, 3p.3 and 12q.33. Von Woweren et al., (2003) from their study on genome scan of 91 
Scandinavian families reported one region on chromosome 14 that reached significance 
threshold and 2 more regions that were suggestive of linkage with early onset hypertension. 
In 26 Utah pedigrees linkage of pulse pressure was suggested with loci on 8p and 12q 
regions by Camp et al., (2003). In a Large Chinese hypertensive kindred with 387 
individuals Gong et al., (2003) found a locus on chromosome 12p that overlapped with the 
region containing the gene for autosomal dominant hypertension with type E brachydactyly 
that was mapped in large Turkish kindred (Schuster et al., 1996). This condition is now 
discovered as due to deletion, a reinsertion and inversion by Bahring et al., (2004). Charles et 
al., (2004) in their review of the GWS studies conducted earlier to 2004 summarized that all 
human chromosomes except for 13 and 20 have loci for blood pressure, hypertension or pre-
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eclampsia. Regions on chromosomes 1,2,8,11,12,15,16,18 and 19 were replicated in more 
than one study and there were 3 cytogenetic intervals on chromosome 2 (2p25.3-p16.3; 
2p16.1-p12; 2q23.3-q24.3) harboring loci for blood pressure that was also replicated in more 
than one study.  Caulfield et al, (2003) associated with British Genetics of hypertension 
(BRIGHT) programme, phenotyped 2010 affected sibling pairs drawn from 1599 severely 
hypertensive families completed 10 Centi Morgan genome wide scan. Their conclusion was 
that human essential hypertension has an oligogenic element (with a few genes involved in 
the determination of the trait) possibly superimposed on more genetic effects, and that 
several genes may be tractable to a positional cloning strategy. In a large sample of 2959 
individuals from 500 families from NHLBI, Hunt et al., (2002) identified five regions with 
lod score suggestive of linkage of hypertension with loci on chromosomes 1,7,12 and 15 and 
evidence of best linkage with a locus on chromosome 6 with systolic blood pressure. In a 
study of 177 Australian Caucasian hypertensive sib-pairs, Rutherford et al, (2004) showed 
significant excess allele sharing of D18S61 marker. At this region adenylate cyclase-
activating polypeptide gene-1 (ADCYAP1) involved in vasodilation shows association with 
hypertension. As a complement to linkage and association studies Zhu et al, (2005) carried 
out admixture mapping using genome scan micro satellite markers among African 
Americans participating in the Lung, and Blood Institute’s Family Blood Pressure 
Programme. Using 269 microsatellite markers the authors concluded that chromosome 6q24 
and chromosome 21q21 may contain genes influencing risk for hypertension in African 
Americans. Kamide et al, (2005) genotyped (796 hypertensives and 1084 normotensives) 47 
polymorphisms in 14 genes lying between nucleotide 8,845,292 and 11,946,689 which 
includes D2S2278 and D2S168 loci on chromosome 2 and concluded that GREB1 and 
HPCAL1 are the candidates for hypertension susceptibility. Chen et al, (2005) conducted 
autosomal genome scan in 775 white siblings and found suggestive  linkage for total area of 
systolic and diastolic blood pressure on chromosome 4 and diastolic blood pressure 
incremental area on chromosome 18. In these regions candidate genes for hypertension like 
alpha and beta adducin, sodium bicarbonate co-transporter and G-protein coupled receptor 
kinase 4 are located.  
In the recent past novel regions in the genome are localized for blood pressure and 
hypertension employing large number of  samples and SNP markers. Org et al. (2009) 
studied 395,102 SNPs in 1,644 individuals from the KORA S3 cohort study, but could not 
find the results reaching significance level of p≤10-8 for blood pressure or hypertension. The 
authors replicated 80 strongest associations with blood pressure and hypertension  in two 
other European cohorts and identified a variant CDH13 (cadherin 13 preprotein) locus 
(rs11646213) to be associated with hypertension and blood pressure. Newton-Chech et al., 
(2009) in the GBP consortium performed largest GWAS study considering blood pressure as 
continuous trait. They identified association of SBP with three loci (MTHFR, CYP17A1 and 
PLCD), DBP with 5 loci (FGF5, C10orf107, SH2B3, CYP1A2 and ZNF 652) at genome wide 
significance levels (p<5 x 10-8). They also found association of 8 variants with hypertension 
in the same direction as blood pressure. Levy et al., (2009) performed for the CHARGE 
group consortium a metanalysis of in 29,136 participants from six different cohort studies 
and with the population of 34,443 from GBP-gen. Their attempt revealed many novel 
variants for DBP and SBP with genome wide level of significance. Use of meta-analysis in 
the GWAS studies helps in achieving near complete genetic coverage. Meta-analysis studies 
by Global BPgen and CHARGE consortia have taken the number of loci to a total of 8 for 
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systolic, 11 for diastolic pressure and 6 for hypertension (Sajjad Rafiq et al., 2010). Yet more 
attempts world wide are needed to fix the genes responsible for the pathogenesis of elevated 
blood pressure in terms of the role played by the genes, epidemiology factors and 
interaction between them. 
4.4 Comparative genomics 
The approach of analyzing genetic basis of any disease is through comparative genomics 
where data from animal studies are used to extrapolate the interpretations about the 
mechanisms to human conditions. For human hypertension animal models offer advantages 
because mating and environment can be controlled. Crossing of inbred strains resolves the 
problem of heterogeneity. Differences in many genes like renin, Na+/K+ ATPase ǂ subunit 
have been reported between hypertensive and normotensive strains of rats. Genetic 
polymorphisms in renin gene of Dahl rats are found to co-segregate with blood pressure in a 
dose dependent way supporting the involvement of the genes in the regulation of blood 
pressure. Similar results on co-segregation was not found for the alleles of Na+/K+ ATPase 
ǂ subunit. Data from the studies on hypertensive rodent strains indicated that genes on 
human chromosome 17 are responsible for human hypertension. Two closely linked 
microsatellite markers D17S183 and D17S934 which are close to ACE gene locus were 
significantly associated with essential hypertension (Julier et al., 1997). The region on human 
chromosome 17 is syntenic to rat chromosome 10. There were also studies refuting 
significant linkage of hypertension to chromosome 17. Study on the translation of QTLs 
between rats and humans predicted 26 chromosomal regions in the human genome that are 
likely to contain genes controlling hypertension (Stoll et al., 2000). Many other studies on 
animal models helped in furthering the knowledge of conserved genomic region involved in 
the regulation of blood pressure and progress in this direction will improve the status of 
knowledge of mechanisms underlying human hypertension. 
5. Future scope for hypertension management 
Despite the fact that effective drugs are available, only about one out of three people has 
their blood pressure successfully controlled, and the blame is attributed to the undesirable 
side effects and the poor oral drug compliance. Keeping in mind the increasing incidence 
of hypertension and the patients inconsistency for the polypharmacy, immunization 
against renin and the angiotensins, although with less success, are being attempted. More 
recently, immunization against angiotensin-I with PMD-3117 vaccine, angiotensin-II with 
CYT006-AngQb vaccine and targeting angiotensin-II type 1A receptor with ATR12181 
vaccine have provided optimism in the development of a hypertension vaccine (Pandey et 
al., 2009). Ang Qb vaccine has proved to become the first vaccine ever to lower (-9/-4 mm 
Hg) blood pressure in human beings (Pandey et al., 2009). Vaccine could induce long 
lasting effects with a dosing interval of months, increasing patient acceptability and 
compliance and thus a better control of high blood pressure.  This approach has a major 
advantage as it can reduce the usage of medication by the patients. The results of this new 
biotherapy for hypertension are intriguing and promising, and vaccination for 
hypertension may turn out to be very useful in many patients. The impact of this 
treatment can revolutionarise the management of essential hypertension- a disease that 
poses public health problems. 
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6. Glossary 
Bonferroni correction: is a multiple-comparison correction used when several  dependent or 
independent statistical tests are performed simultaneously  
Candidate gene study: A study of specifically selected (candidate) genes in which variation 
is hypothesized to influence the risk of a disease. 
Diastolic blood Pressure: represents the minimum pressure in the arteries when the heart is 
at rest. 
Dominant Model: This model specifically tests the association of having at least one minor 
allele say ‘a’ (either Aa or aa) versus not having it at all (AA). 
Epistatic Interaction: An epistatic interaction between two genes (non allelic) occurs when 
the phenotypic impact of one gene depends on another gene, often exposing a functional 
association between them. 
Hardy-Weinburg equilibrium: An idealised state in which gene and genotypic frequencies 
in populatioin do not change from generation to generation in the absence of migration, 
genetic drift, selection 
Haplotype: is a set of closely linked genetic markers present on one chromosome of the 
homologous pair which tend to be inherited together and not easily separable by 
recombination. 
Heretability: Heritability is the proportion of variation in a phenotype (trait, characteristic 
or physical feature) that is thought to be caused by genetic variation among individuals. It is 
a measure of the degree to which the variance in the distribution of a phenotype is due to 
genetic causes. In the broad sense it is measured by the total genetic variance divided by the 
total phenotypic variance. In the narrow sense it is measured by the genetic variance due to 
additive genes divided by the total phenotypic variance. 
Hypertension (HTN): or high blood pressure is a cardiac chronic medical condition in 
which the systemic arterial blood pressure is elevated above the normal levels 
Linkage: Linkage is the tendency of phenotypes marker alleles etc., to co-segregate in a 
pedigree because their determinants lie close together on a given chromosome. 
Linkage Disequilibrium: Non random association of the gens present on the same or any 
other chromosome.  
Odds Ratio:  is one of a range of statistics used to assess the risk of a particular outcome (or 
disease) if a certain factor (or exposure) is present. 
Pleiotropy: Pleiotropy is the phenomenon whereby a single gene has multiple consequences 
in numerous tissues. Pleiotropic effects stem from both normal and mutated genes, but 
those caused by mutations are often more noticeable and easier to study. 
Polymorphism: Genetic Polymorphism is the presence of more than two allelic forms at a 
given locus in such frequencies that the rarest of them is not just due to recurring mutations 
but is due to a phenomenon called “polymorphisms”. The frequency of the rarest 
allele/form as a rule is taken as > 1.0% 
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Recessive Model: This model specifically tests the association of having the minor allele “a” 
as both alleles (aa) versus having at least one major allele d (Aa or AA). 
Systolic Blood Pressure: represents the maximum pressure exerted in the arteries when the 
heart contracts. 
Tagged SNPs: are representative single nucleotide polymorphisms (SNP) in a region of the 
genome with high linkage disequilibrium  
Transmission disequilibrium test (TDT): A family-based study to compare the proportion 
of alleles transmitted (or inherited) from a heterozygous parent to an affected child. Any 
significant deviation from 0.50 in transmission ratio implies an association. 
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